P103. Targeting nitric oxide to macrophages with prodrugs of the O2-glycosylated diazeniumdiolate family
Larry K. Keefer(Unknown), Christian Bogdan(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ulrike Schleicher(Friedrich-Alexander-Universität Erlangen-Nürnberg), Brett M. Showalter(Frederick National Laboratory for Cancer Research), Carlos A. Valdez(Frederick National Laboratory for Cancer Research), Joseph E. Saavedra(Genesis Laboratories), Keith M. Davies(George Mason University)
Cited by 0
Related Papers
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k
“NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms
|Methods in enzymology on CD-ROM/Methods in enzymology|1996|674
Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock
|Nature Immunology|2003|363
Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination
|Science Immunology|2022|280
Nitric Oxide-Releasing Polymers Containing the [N(O)NO]<sup>-</sup>Group
|Journal of Medicinal Chemistry|1996|207